From: Characterization and risk estimate of cancer in patients with primary Sjögren syndrome
Author | Year | Country | Setting | Primary SjS patients (n) | Mean folow-up (yrs/pat-years) | Population cancer registry/classif | Hemat neoplasia classif | Cancer (n) | All-cancer SIR (95% CI) | Specific solid cancer SIR | Hemat cancers (n) | NHL (n) | MALT (n) | DLBC (n) | MZ (n) | Myel (n) | Other B-cell | Non-B-cell | NHL SIR (95% CI) | MM SIR (95% CI) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Theander | 2006 | Sweden | Hosp | 286 | jul-64 | Swedish Cancer Reg/ICD7 | WHO 2001 | 33 | 1.42 (0.98–2.00) | NA | 12 | 11 | 1 | 7 | 0 | 2 | 1 | T-cell (1) | 15.6 (7.8–27.8) | 3.27 (0.1–18.2) |
Baimpa | 2009 | Greece | Hosp | 536 | 2.6/ND | NA | ND | ND | NA | NA | 40 | 38 | 21 | 7 | 5 | 0 | 5 | HD (1), T-cell (1) | NA | ND |
Zhang | 2010 | China | Hosp | 1320 | 4.4/ND | Shangai Reg/ICD10 | WHO 2001 | 29 | 3.25 (2.12–4.52) | NA | 10 | 8 | 2 | 2 | 0 | 0 | 3 | T-cell (1) | 48.1 (20.7–94.8) | 37.9 (4.58–136.7) |
Weng | 2012 | Taiwan | Pop | 7852 | ND/27246 | NHI/ICD9 | ICD9 | 227 | 1.01 (0.74–1.35) | Colon 0.22 (0.05–0.6); Thyroid 2.56 (1.4–4.3) | 31 | 23 | ND | ND | ND | ND | ND | ND | 7.1 (4.2–10.3) | 6.1 (2.0–14.2) |
Baldini | 2012 | Italy | Hosp | 563 | 6/ND | NA | WHO 2001 | NA | NA | NA | NA | 12 | 8 | 3 | 1 | 0 | 0 | ND | NA | ND |
Hemminki | 2012 | Sweden | Pop | 1516 | ND/16700 | Swedish Cancer Reg/ICD | NA | NA | NA | Breast 0.46 (0.26–0.75) | NA | NA | ND | ND | ND | ND | ND | ND | NA | ND |
Johnsen | 2013 | Norway | Pop | 443 | ND/3813 | Norway Reg/ICD10 | ICD10 | NA | NA | NA | NA | 7 | 6 | 0 | 1 | 0 | 0 | ND | 9.0 (7.1–26.3) | ND |
Risselada | 2013 | Netherl | Hosp | 195 | 7.7/ND | NA | WHO 2001 | NA | NA | NA | NA | 21 | 10 | 8 | 3 | 0 | 0 | ND | NA | ND |
Quartuccio | 2014 | Italy | Hosp | 661 | ND | NA | ND | NA | NA | NA | NA | 40 | ND | ND | ND | ND | ND | ND | NA | ND |
Papageorgiou | 2015 | Greece | Hosp | ND | ND | ND | WHO | ND | ND | ND | ND | 77 | 51 | 12 | 8 | 0 | 6 | ND | ||
Nocturne | 2016 | France | Hosp | ND | ND | ND | WHO | ND | ND | ND | ND | 99 | 58 | 17 | 18 | 0 | 6 | HD (1), T-cell (1) | ND | ND |
Present study | 2016 | Spain | Hosp | 1300 | 7.6/ND | GLOBOCAN/ICD10 | WHO 2016 | 122 | 1.91 (1.6–2.28) | Thyroid 5.17 (1.94–13.79); Lip/oral 4.81 (1.81–12.83); Stomach 2.53 (1.05–6.07) | 61 | 12 | 27 | 7 | 4 | 2 | 6 | HD (4), T-cell (3), myeloid/leuk (8) | 6.04 (3.43–10.64) | 36.17 (25.44–51.43) |